Search

Your search keyword '"Cerquaglia A"' showing total 18 results
Start Over Author "Cerquaglia A" Topic visual acuity
18 results on '"Cerquaglia A"'

1. UVEITIS TREATED WITH DEXAMETHASONE IMPLANT.

Author

Mathis T, Cerquaglia A, Weber M, Guillarme-Sallit R, Malclès A, Voirin N, Servant M, Sudhalkar A, Bilgic A, Denis P, Sève P, Bodaghi B, and Kodjikian L

Subjects
Female, Glucocorticoids administration & dosage, Humans, Intravitreal Injections, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Uveitis diagnosis, Vitreous Body, Dexamethasone administration & dosage, Drug Implants, Macula Lutea diagnostic imaging, Uveitis drug therapy, Visual Acuity
Abstract

Purpose: To evaluate the real-life efficacy and safety of the intravitreal dexamethasone implant in uveitis., Methods: This retrospective observational multicentric study included 152 eyes treated exclusively by 358 dexamethasone implant injections. The main outcome measures included change in the best-corrected visual acuity, central macular thickness, and vitreous haze score., Results: Patients were treated with dexamethasone implant for macular edema (51.3%), vitritis with macular edema (40.1%), vitritis (5.3%), and other causes (3.3%). The mean duration of follow-up was 19.0 months. The mean gain in best-corrected visual acuity during follow-up was +12.1 letters. An improvement in best-corrected visual acuity ≥5, 10, and 15 letters was found in 64.5, 50.7, and 35.5% of cases, respectively. 59.7% of eyes with macular edema at baseline were found to be anatomical responders. Vitritis resolution (vitreous haze = 0+) was obtained in 81.4% of cases. Ocular hypertension (intraocular pressure ≥25 mmHg and/or gain ≥10 mmHg from baseline) occurred in 28.3% of patients. No filtering surgery/laser therapy was required. A total of 40.2% of phakic subjects underwent cataract surgery on average 11.2 months after the first injection., Conclusion: This study confirms the efficacy and safety of the dexamethasone implant in noninfectious uveitis. Cataract and ocular hypertension were not uncommon but easily manageable., Competing Interests: T. Mathis declared conflicts of interest from Allergan, Bayer, and Novartis; M. Weber declared conflicts of interest from Allergan; P. Denis declared conflicts of interest from Allergan and Novartis; B. Bodaghi declared conflicts of interest from AbbVie, Allergan, Alimera, and Santen; L. Kodjikian declared conflicts of interest from AbbVie, Allergan, Bayer, Novartis, Roche, and Théa. None of the other authors has any financial interests to disclose.

Published
2021
Full Text
View/download PDF

2. Choroidal Vascular Changes in Multiple Evanescent White Dot Syndrome.

Author

Pellegrini M, Veronese C, Bernabei F, Lupidi M, Cerquaglia A, Invernizzi A, Zicarelli F, Cimino L, Bolletta E, Vagge A, and Ciardella AP

Subjects
Adolescent, Adult, Disease Progression, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Young Adult, Choroid blood supply, Retinal Vessels diagnostic imaging, Tomography, Optical Coherence methods, Visual Acuity, White Dot Syndromes diagnosis
Abstract

Purpose : To evaluate choroidal structural changes in patients with multiple evanescent white dot syndrome (MEWDS) during the acute and recovery stages. Methods : Enhanced-depth imaging optical coherence tomography (EDI-OCT) scans of 16 patients with unilateral MEWDS were acquired during the acute and recovery stages in both eyes. Images were binarized with the ImageJ software to measure subfoveal choroidal thickness (CT), total choroid area, luminal area and choroidal vascularity index (CVI). Results : In the acute stage, subfoveal CT, total choroidal area and CVI were significantly higher in eyes with MEWDS compared to fellow eyes (371.2 ± 101.8 vs 317.1 ± 90.3 µm, p = .001; 2.826 ± 0.686 vs 2.524 ± 0.674 mm 2 , p = .014; 69.49 ± 3.51 vs 68.27 ± 3.41%, p = .044, respectively). In the recovery stage, subfoveal CT, total choroidal area and CVI in eyes with MEWDS significantly decreased to respectively 333.4 ± 90.5 µm, p = .007, 2.592 ± 0.570 p = .002, and 67.31 ± 2.74%, p = .014. Conclusions : Choroidal thickness and vascularity are significantly increased during the acute stage of MEWDS.

Published
2021
Full Text
View/download PDF

3. Effect of preoperative topical nepafenac 0.1% on inflammatory response after uncomplicated cataract surgery in healthy subjects.

Author

Cagini C, Cerquaglia A, Pellegrino A, Iannone A, Lupidi M, and Fiore T

Subjects
Administration, Topical, Aged, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Prospective Studies, Tomography, Optical Coherence, Treatment Outcome, Benzeneacetamides administration & dosage, Cataract Extraction, Phenylacetates administration & dosage, Postoperative Complications prevention & control, Preoperative Care methods, Visual Acuity
Abstract

Purpose: To determine the effect of preoperative topical Nepafenac administration on anterior chamber flare after uneventful cataract surgery in healthy subjects., Methods: Prospective randomized clinical trial. Seventy-three eyes of 73 healthy patients undergoing routine cataract surgery were randomized to receive (group A) topical nepafenac (1 mg/ml) or not to receive (group B) 1 drop 3 times per day for 3 days before surgery. All eyes received the same postoperative anti-inflammatory therapy. Clinical outcome parameters such as best corrected visual acuity, intraocular pressure, retinal central foveal thickness and aqueous flare were recorded preoperatively, 1, 15, 30 and 60 days after surgery., Results: Three patients were excluded for poor compliance, and three patients were excluded or developing pseudophakic macular oedema during the follow-up. Both groups were comparable for age, gender, and showed similar BCVA, intraocular pressure and central macular thickness values preoperatively and during the entire follow-up (p > 0.01). Aqueous flare values showed a statistically increase in both groups respect to preoperative values through follow-up evaluations (p < 0.01), while values were significantly lower in group A than in group B 30 days after surgery (p < 0.01)., Conclusion: Preoperative administration of topical Nepafenac reduces the inflammatory response in healthy patients undergoing uncomplicated cataract surgery one month after surgery respect to non-treated group., (© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

4. Choroidal vasculature analysis in MEK inhibitor-associated retinopathy

Author

Alessio Cerquaglia, Marco Lupidi, Jay Chhablani, Ramkailash Gujar, Barbara Iaccheri, Tito Fiore, Daniela Fruttini, Antonello Ramundo, Kiran Kumar Vupparaboina, Luca Castellani, Edoardo Simonetti, Luca De Carolis, Enrico Tiacci, Brunangelo Falini, and Carlo Cagini

Subjects
Mitogen-Activated Protein Kinase Kinases, Visual Acuity, General Medicine, choroidal vascularity index, serous retinopathy, Ophthalmology, Retinal Diseases, Humans, retinal toxicity, MEK inhibitor-associated retinopathy, sense organs, Protein Kinase Inhibitors, choroid, Tomography, Optical Coherence
Abstract

Purpose To evaluate choroidal vascularity index (CVI) in patients developing mitogen-activated protein kinase kinase (MEK) inhibitor-associated retinopathy (MEKAR). Methods In this prospective observational study, extensive ophthalmic examination was performed, including enhanced-depth-imaging-optical coherence tomography (EDI-OCT). EDI-OCT scans of patients receiving Cobimetinib, taken at baseline and at MEKAR manifestation, were considered for choroid analysis. Choroidal thickness (CT) was measured on high-resolution b-scans passing through the fovea at three different locations. Same scans were therefore imported for binarization into a previously reported software and CVI was calculated as the ratio of luminal area (LA) to total choroid area (TCA). Results When compared to baseline, eyes with MEKAR (14 eyes) did not show significative CT variation in subfoveal region (p = 0,57), 750-µm-nasal to the fovea (p = 0,08) and 750-µm-temporal to the fovea (p = 0,07). Similarly, there were no statistically significant differences for TCA (p = 0.54), LA (p = 0.85), stromal area (SA) (p = 0.13), LA/SA (p = 0.34) and CVI (p = 0.47). Best-corrected visual acuity was significantly reduced at fluid accumulation when compared to baseline values (p = 0.03), with complete recovery after fluid resolution (p = 0.73). Conclusion Multiple parameters reflecting the status of the choroid seemed not influenced by Cobimetinib administration. Retinal pigment epithelium toxic disfunction likely represents the crucial step in MEKAR pathogenesis.

Published
2022

5. Comparison of the Effect of Diclofenac 0.1% and Nepafenac 0.1% on Aqueous Flare in Patients Undergoing Cataract Surgery: A Prospective Randomized Study

Author

Marco Lupidi, Carlo Cagini, Barbara Iaccheri, Tito Fiore, Adriana Pellegrino, and Alessio Cerquaglia

Subjects
Male, medicine.medical_specialty, Diclofenac, Pseudophakia, medicine.medical_treatment, Benzeneacetamides, Visual Acuity, cataract surgery, diclofenac, laser flare meter, nepafenac, Postoperative inflammation, Administration, Ophthalmic, Slit Lamp Microscopy, Nepafenac, law.invention, Aqueous Humor, Cellular and Molecular Neuroscience, Double-Blind Method, Lens Implantation, Intraocular, law, Ophthalmology, medicine, Humans, Prospective randomized study, In patient, Prospective Studies, Intraocular Pressure, Aged, Phenylacetates, Aged, 80 and over, Phacoemulsification, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Middle Aged, Cataract surgery, Uveitis, Anterior, Sensory Systems, stomatognathic diseases, Female, Ophthalmic Solutions, business, medicine.drug, Flare
Abstract

To compare, using laser flare meter (LFM), the efficacy of topical nepafenac 0.1, % and diclofenac 0.1% ophthalmic solution in the control of anterior chamber inflammation after uncomplicated cataract surgery.Patients undergoing phacoemulsification for age-related cataract were recruited. Complete evaluation with visual acuity, slit-lamp examination, endothelial cell density, intraocular pressure, retinal tomography and anterior chamber flare evaluation was performed before surgery and 1, 15, 30 and 60 days after surgery. Patients were randomly assigned to receive topical diclofenac 0.1% 4 times a day for four weeks or nepafenac 0.1% 3 times a day for three weeks in addition to topical steroids and antibiotic.64 (31 males, mean age 77.3 ± 5.9) patients were enrolled. Half of them were randomly assigned to group A (diclofenac 0.1%) and half to group B (nepafenac 0.1%). There was a statistically significant visual acuity improvement postoperatively in both groups, with no statistical difference between the groups. Intraocular pressure, corneal thickness, endothelial cells count and macular thickness parameters didn't significantly vary between before and after surgery. One-day after surgery, aqueous flare was significantly higher (22,27 ± 9,25 ph/ms in group A and 22,36 ± 7,47 in group B) than before surgery (14,59 ± 7,16 ph/ms in group A and 11,84 ± 4,44 in group B) in both groups, then declining in the first month and reaching preoperative levels again by 2 months in both groups. In group B, LFM values at 15 and 30 days after surgery were significantly lower (13,59 ± 4,80 and 14,07 ± 5,01) than in group A (17,00 ± 6,97 and 16,96 ± 6,13).Nepafenac ensured a better inflammation control than diclofenac during the first month.

Published
2020
Full Text
View/download PDF

6. UVEITIS TREATED WITH DEXAMETHASONE IMPLANT

Author

Michel Weber, Pascal Sève, Thibaud Mathis, Bahram Bodaghi, Laurent Kodjikian, Rébecca Guillarme-Sallit, Nicolas Voirin, Marion Servant, Aditya Sudhalkar, Ariane Malclès, Philippe Denis, Alper Bilgic, Alessio Cerquaglia, Institut de la Vision, Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), Hôpital de la Croix-Rousse [CHU - HCL], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Male, Intraocular pressure, medicine.medical_specialty, Visual acuity, genetic structures, medicine.medical_treatment, Visual Acuity, Ocular hypertension, Dexamethasone, [SPI.MAT]Engineering Sciences [physics]/Materials, Uveitis, 03 medical and health sciences, 0302 clinical medicine, Ophthalmology, Medicine, Humans, Macula Lutea, Macular edema, Glucocorticoids, Retrospective Studies, Drug Implants, business.industry, General Medicine, Cataract surgery, Middle Aged, medicine.disease, eye diseases, 3. Good health, Vitreous Body, 030104 developmental biology, Treatment Outcome, Intravitreal Injections, 030221 ophthalmology & optometry, Female, Implant, sense organs, medicine.symptom, business, medicine.drug
Abstract

PURPOSE To evaluate the real-life efficacy and safety of the intravitreal dexamethasone implant in uveitis. METHODS This retrospective observational multicentric study included 152 eyes treated exclusively by 358 dexamethasone implant injections. The main outcome measures included change in the best-corrected visual acuity, central macular thickness, and vitreous haze score. RESULTS Patients were treated with dexamethasone implant for macular edema (51.3%), vitritis with macular edema (40.1%), vitritis (5.3%), and other causes (3.3%). The mean duration of follow-up was 19.0 months. The mean gain in best-corrected visual acuity during follow-up was +12.1 letters. An improvement in best-corrected visual acuity ≥5, 10, and 15 letters was found in 64.5, 50.7, and 35.5% of cases, respectively. 59.7% of eyes with macular edema at baseline were found to be anatomical responders. Vitritis resolution (vitreous haze = 0+) was obtained in 81.4% of cases. Ocular hypertension (intraocular pressure ≥25 mmHg and/or gain ≥10 mmHg from baseline) occurred in 28.3% of patients. No filtering surgery/laser therapy was required. A total of 40.2% of phakic subjects underwent cataract surgery on average 11.2 months after the first injection. CONCLUSION This study confirms the efficacy and safety of the dexamethasone implant in noninfectious uveitis. Cataract and ocular hypertension were not uncommon but easily manageable.

Published
2021
Full Text
View/download PDF

7. Real-world outcomes of anti-VEGF therapy in treatment-naïve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study

Author

Alessio Muzi, Alessio Cerquaglia, Tito Fiore, Marco Lupidi, Carlo Cagini, Daniela Fruttini, Ramkailash Gujar, Jay Chhablani, Stefano Schiavon, and Michele Reibaldi

Subjects
medicine.medical_specialty, genetic structures, Visual Acuity, neovascular AMD, Angiogenesis Inhibitors, optical coherence tomography angiography, Lesion, Therapy naive, Macular Degeneration, Oct angiography, Ranibizumab, Ophthalmology, Humans, Medicine, Fluorescein Angiography, age-related macular degeneration, Aflibercept, Anti vegf, optical coherence tomography, medicine.diagnostic_test, business.industry, Antibodies, Monoclonal, anti-VEGF therapy, General Medicine, Optical coherence tomography angiography, Macular degeneration, Fluorescein angiography, medicine.disease, eye diseases, Treatment Outcome, Intravitreal Injections, Wet Macular Degeneration, sense organs, medicine.symptom, business, Tomography, Optical Coherence, Follow-Up Studies, medicine.drug
Abstract

Purpose To compare the 12 months visual and anatomical outcomes of treatment-naive neovascular age-related macular degeneration (nAMD) patients diagnosed by optical coherence tomography angiography (OCT-A) compared with fluorescein angiography (FA)/indocyanine green angiography (ICGA), after anti-VEGF treatment in a real-world setting. Methods Monocentric, observational, parallel-group study of nAMD patients diagnosed with either FA/ICGA or non-invasive OCT-A methods. Patients were treated with a fixed dosing regimen of intravitreal ranibizumab or aflibercept and followed up for 12 months. Primary outcomes were the 12 months functional (BCVA) and anatomical (CST reduction) gains between the two groups. The stratification of BCVA and CST gains by type of neovascular lesion and by anti-VEGF treatment was also assessed. Results Seventy-two patients received FA/ICGA for the initial diagnosis of nAMD, while 73 received OCT-A. Overall, the mean BCVA gain at 12 months was 11.5 ± 9.6 letters. There were no statistically significant differences between the invasive and non-invasive imaging groups in BCVA gain (p = 0.87) or CST reduction (p = 0.76). No statistically significant outcome differences between different lesion types and the two drugs were observed. Conclusion In a real-world setting, nAMD patients diagnosed with OCT-A showed meaningful improvements in visual and anatomical parameters during 12 months of treatment, without significant differences with those diagnosed by invasive modalities.

Published
2021

8. New Insights On Ocular Sarcoidosis: An Optical Coherence Tomography Angiography Study

Author

Barbara Iaccheri, Federica Benedetta Belli, Tito Fiore, Carlo Cagini, Marco Lupidi, Moncef Khairallah, Alessio Cerquaglia, and Daniela Fruttini

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, Sarcoidosis, genetic structures, Amplitude decorrelation angiography, inflammation, optical coherence tomography angiography, sarcoidosis, uveitis, Fundus Oculi, Visual Acuity, Uveitis, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Immunology and Allergy, Macula Lutea, Fluorescein Angiography, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, Reproducibility of Results, Retinal Vessels, Optical coherence tomography angiography, Middle Aged, Fluorescein angiography, medicine.disease, eye diseases, Ophthalmology, Cross-Sectional Studies, 030104 developmental biology, 030221 ophthalmology & optometry, Female, sense organs, Radiology, business, Tomography, Optical Coherence, Ocular sarcoidosis, Follow-Up Studies
Abstract

Purpose: To report optical coherence tomography angiography (OCT-A) findings in eyes with ocular sarcoidosis (OS) and to compare these findings with those of fluorescein angiography (FA).Me...

Published
2018
Full Text
View/download PDF

9. Tear Film Stability in Sjögren Syndrome Patients Treated with Hyaluronic Acid Versus Crosslinked Hyaluronic Acid-Based Eye Drops

Author

Tito Fiore, Giovanni Torroni, Marco Lupidi, Barbara Iaccheri, Carlo Cagini, Alessio Cerquaglia, and Pasquale Aragona

Subjects
0301 basic medicine, medicine.medical_specialty, eye drops, Visual Acuity, Sjögren Syndrome, crosslinked hyaluronic acid, stability, tear film, Administration, Ophthalmic, Sjögren syndrome, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Ophthalmology, Hyaluronic acid, medicine, Humans, Pharmacology (medical), In patient, Hyaluronic Acid, Pharmacology, business.industry, Corneal Topography, Middle Aged, medicine.disease, eye diseases, Cross-Linking Reagents, Sjogren's Syndrome, 030104 developmental biology, chemistry, Tears, 030221 ophthalmology & optometry, Female, sense organs, Ophthalmic Solutions, business
Abstract

To compare the stability of the tear film after instillation of eye drops containing hyaluronic acid (HA) or crosslinked hyaluronic acid (CLHA)-based in patients with Sjögren syndrome-related dry eye (SSDE).Forty subjects were included in this study and were divided into 2 groups: the first group (control group) consisted of 20 healthy volunteers; the second group (study group) constituted of 20 suffering from SSDE; before and 5, 30, and 60 min after instillation of eye drops the surface regularity index (SRI) and surface asymmetry index (SAI) were registered.Comparing HA and CLHA, in the control group, SAI show statistically significant difference in the time 0 and in time 5, whereas there is no a statistically significant difference after 30 and 60 min from instillation. For SRI there is no statistically significant difference at any time. In SSDE group there is no statistically significant difference in the time 0 and 5, whereas there is a statistically significant difference after 60 min for SAI, and after 30 and 60 min for SRI from instillation. Both SRI and SAI in dry eyes were significantly greater than in control eyes (P 0.05).Our study showed a better efficacy of CLHA compared with HA in maintaining the stability of the tear film in a patient suffering from SSDE.

Published
2017
Full Text
View/download PDF

10. Inflammatory Choroidal Neovascularization: Beyond the Intravitreal Approach

Author

Tito Fiore, Christine Fardeau, Phuc LeHoang, Carlo Cagini, and Alessio Cerquaglia

Subjects
Male, Vascular Endothelial Growth Factor A, Pathology, Visual Acuity, Angiogenesis Inhibitors, Neovascularization, 0302 clinical medicine, Panuveitis, Immunology and Allergy, Fluorescein Angiography, Choroid, inflammation, neovascularization, therapy, uveitis, Middle Aged, humanities, Bevacizumab, Choroidal neovascularization, medicine.anatomical_structure, Intravitreal Injections, Drug Therapy, Combination, Female, medicine.symptom, Tomography, Optical Coherence, Uveitis, Adult, medicine.medical_specialty, Adolescent, Inflammation, Young Adult, 03 medical and health sciences, Ranibizumab, medicine, Humans, Glucocorticoids, Retrospective Studies, business.industry, Uveitis, Posterior, medicine.disease, Choroidal Neovascularization, eye diseases, body regions, Ophthalmology, 030221 ophthalmology & optometry, sense organs, business, 030217 neurology & neurosurgery
Abstract

To describe the importance of a customized combined systemic and local therapy in the management of inflammatory choroidal neovascularization (iCNV).Observational retrospective case series.Four iCNV cases, complicating posterior uveitis or panuveitis affecting young patients, are reported. Combination of both intravitreal (IVT) and systemic drugs represented a successful treatment strategy.iCNV is a sight-threatening disease which affects mostly young people. Customized and both systemic and IVT therapies might represent the best therapeutic option in order to obtain disease control and good prognosis.

Published
2017
Full Text
View/download PDF

11. Full-thickness choroidal thinning as a feature of Fuchs Uveitis Syndrome: quantitative evaluation of the choroid by Enhanced Depth Imaging Optical Coherence Tomography in a cohort of consecutive patients

Author

Giovanni Torroni, Barbara Iaccheri, Tito Fiore, Daniela Fruttini, Alessio Cerquaglia, Carlo Cagini, Marco Lupidi, and Claudia Giacalone

Subjects
Adult, Male, medicine.medical_specialty, Biometry, Visual acuity, genetic structures, Visual Acuity, Iridocyclitis, Cohort Studies, Uveitis, Tonometry, Ocular, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Optical coherence tomography, Ophthalmology, medicine, Humans, Prospective Studies, Prospective cohort study, Slit Lamp, Slit lamp, medicine.diagnostic_test, Choroid, business.industry, Choroid Diseases, Fuchs Uveitis Syndrome, Middle Aged, medicine.disease, eye diseases, Sensory Systems, medicine.anatomical_structure, Choroidal thickness, Enhanced depth imaging, Cohort, 030221 ophthalmology & optometry, Female, sense organs, medicine.symptom, business, Tomography, Optical Coherence, 030217 neurology & neurosurgery
Abstract

To perform a quantitative analysis of choroidal thickness in patients with Fuchs Uveitis Syndrome (FUS) using enhanced depth imaging optical coherence tomography (EDI-OCT). All patients underwent comprehensive ophthalmic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, applanation tonometry, axial length measurements with a swept-source biometer (IOLMaster 700, Carl Zeiss Medic AG, Jena, Germany) and macular 30° linear EDI- B-scan SD-OCT section (Spectralis HRAII+OCT, Heidelberg Engineering, Heidelberg, Germany) in both eyes. Analysis of choroidal thickness was performed at three different locations: subfoveally, 750 μm nasally, and 750 μm temporally to the fovea. Patients having received any surgery or intravitreal injections in the last 12 months and with axial length variance ≥ 1 mm between both eyes were excluded. Sixteen eyes of eight consecutive patients with unilateral FUS were included. Segmented analysis of the choroid, separately considering Haller’s layer and Sattler’s–choriocapillaris layers, showed statistically significant lower values (p

Published
2016
Full Text
View/download PDF

12. Choroidal Vascular Changes in Multiple Evanescent White Dot Syndrome

Author

Federico Zicarelli, Chiara Veronese, Aldo Vagge, Marco Pellegrini, Alessandro Invernizzi, Marco Lupidi, Antonio P. Ciardella, Elena Bolletta, Luca Cimino, Alessio Cerquaglia, and Federico Bernabei

Subjects
Adult, Male, Choroidal thickness, choroidal vascularity index, enhanced depth imaging, multiple evanescent white dot syndrome, optical coherence tomography, Adolescent, Multiple evanescent white dot syndrome, Visual Acuity, NO, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Nuclear magnetic resonance, Optical coherence tomography, medicine, Humans, Immunology and Allergy, In patient, Retrospective Studies, Choroidal thickness, choroidal vascularity index, enhanced depth imaging, multiple evanescent white dot syndrome, optical coherence tomography, 030203 arthritis & rheumatology, White Dot Syndromes, medicine.diagnostic_test, Choroid, business.industry, Retinal Vessels, medicine.disease, eye diseases, Ophthalmology, Disease Progression, 030221 ophthalmology & optometry, Female, sense organs, Enhanced depth imaging, business, Tomography, Optical Coherence, Follow-Up Studies
Abstract

Purpose: To evaluate choroidal structural changes in patients with multiple evanescent white dot syndrome (MEWDS) during the acute and recovery stages.Methods: Enhanced-depth imaging optical cohere...

Published
2019

13. Comparison of anti-inflammatory effects of eye drops formulations after uncomplicated cataract surgery.

Author

Cagini, Carlo, Pellegrino, Adriana, Iannone, Alessia, Cerquaglia, Alessio, Modugno, Antonella, Fiore, Tito, and Messina, Marco

Subjects
ANTI-inflammatory agents, AQUEOUS humor, CATARACT surgery, COMBINATION drug therapy, COMPARATIVE studies, CORNEA, INTRAOCULAR pressure, OPHTHALMIC drugs, PHARMACEUTICAL chemistry, QUINOLONE antibacterial agents, TOBRAMYCIN, VISUAL acuity, DEXAMETHASONE, DESCRIPTIVE statistics, PHARMACODYNAMICS
Abstract

Aim: The aim of this study is to compare the efficacy of different dexamethasone eye drops formulations in controlling postoperative inflammation. Methods: Cataract surgery was carried out in 72 patients (35 males) divided into two groups: group A (36 patients, mean age = 78.0 ± 5.6) received four times daily for 2 weeks a suspension containing tobramycin 0.3% mg/ml + dexamethasone 0.1% mg/ml, and group B (36 patients, mean age = 76.2 ± 6.8) a solution containing tobramycin 0.3% mg/ml + dexamethasone 0.1% mg/ml. Both groups received ofloxacin 0.5% four times daily for 7 days, and nepafenac 0.1% three times daily for 3 weeks. Best-corrected visual acuity, intraocular pressure, corneal thickness, endothelial cells count, aqueous flare and macular thickness were evaluated preoperatively and at 1 day, 15 days, 1 and 2 months. Results: In group A, intraocular pressure, corneal thickness and aqueous humour flare values preoperatively and at the end of follow-up were 14.3 ± 1.8 and 13.2 ± 1.8 mmHg, 546.4 ± 34.6 and 539.6 ± 36.1 µm, 11.84 ± 4.44 and 13.52 ± 5.54 ph/ms, respectively, with no statistically significant difference. In group B, intraocular pressure, corneal thickness and aqueous humour flare values preoperatively and at the end of follow-up were 14.3 ± 1.5 and 13.1 ± 1.7 mmHg, 552.9 ± 37.4 and 548.1 ± 39.3 µm, 11.45 ± 4.06 and 13.73 ± 4.99 ph/ms, respectively, with no statistically significant difference. No difference was detected in the macular thickness values in the parafoveal area preoperatively and at 2 months follow-up in group A (332.18 ± 16.19 and 337.71 ± 16.33 µm) and group B (329.11 ± 18.28 and 334.37 ± 20.86 µm), respectively. Conclusion: The two different formulations of dexamethasone eye drops reached the same anti-inflammatory effects. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

14. Comparison of the Effect of Diclofenac 0.1% and Nepafenac 0.1% on Aqueous Flare in Patients Undergoing Cataract Surgery: A Prospective Randomized Study.

Author

Cagini, Carlo, Pellegrino, Adriana, Cerquaglia, Alessio, Iaccheri, Barbara, Lupidi, Marco, and Fiore, Tito

Subjects
CATARACT surgery, DICLOFENAC, RETINAL surgery, PHACOEMULSIFICATION, INTRAOCULAR pressure, VISUAL acuity, FLARES
Abstract

To compare, using laser flare meter (LFM), the efficacy of topical nepafenac 0.1, % and diclofenac 0.1% ophthalmic solution in the control of anterior chamber inflammation after uncomplicated cataract surgery. Patients undergoing phacoemulsification for age-related cataract were recruited. Complete evaluation with visual acuity, slit-lamp examination, endothelial cell density, intraocular pressure, retinal tomography and anterior chamber flare evaluation was performed before surgery and 1, 15, 30 and 60 days after surgery. Patients were randomly assigned to receive topical diclofenac 0.1% 4 times a day for four weeks or nepafenac 0.1% 3 times a day for three weeks in addition to topical steroids and antibiotic. 64 (31 males, mean age 77.3 ± 5.9) patients were enrolled. Half of them were randomly assigned to group A (diclofenac 0.1%) and half to group B (nepafenac 0.1%). There was a statistically significant visual acuity improvement postoperatively in both groups, with no statistical difference between the groups. Intraocular pressure, corneal thickness, endothelial cells count and macular thickness parameters didn't significantly vary between before and after surgery. One-day after surgery, aqueous flare was significantly higher (22,27 ± 9,25 ph/ms in group A and 22,36 ± 7,47 in group B) than before surgery (14,59 ± 7,16 ph/ms in group A and 11,84 ± 4,44 in group B) in both groups, then declining in the first month and reaching preoperative levels again by 2 months in both groups. In group B, LFM values at 15 and 30 days after surgery were significantly lower (13,59 ± 4,80 and 14,07 ± 5,01) than in group A (17,00 ± 6,97 and 16,96 ± 6,13). Nepafenac ensured a better inflammation control than diclofenac during the first month. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

15. Deep inside Multifocal Choroiditis: an Optical Coherence Tomography Angiography approach

Author

Alessio Cerquaglia, Barbara Iaccheri, Tito Fiore, Paolo Perri, Marco Lupidi, and Carlo Cagini

Subjects
Male, Retinal Ganglion Cells, Pathology, medicine.medical_specialty, Inflammatory choroidal neovascularization, Multifocal choroiditis, Optical coherence tomography angiography, Uveitis, Choroiditis, Visual acuity, genetic structures, Fundus Oculi, Visual Acuity, NO, 03 medical and health sciences, 0302 clinical medicine, Ophthalmology, medicine, Humans, Medicine (all), Fluorescein Angiography, Retinal pigment epithelium, medicine.diagnostic_test, Choroid, business.industry, Blind spot, Middle Aged, Fluorescein angiography, medicine.disease, Choroidal Neovascularization, eye diseases, medicine.anatomical_structure, Choroidal neovascularization, 030221 ophthalmology & optometry, Bruch Membrane, sense organs, medicine.symptom, business, Tomography, Optical Coherence, 030217 neurology & neurosurgery
Abstract

The aim of the study was to report the clinical utility of optical coherence tomography angiography (OCT-A) in characterizing and differentiating inflammatory lesions and choroidal neovascularization (CNV) in multifocal choroiditis (MFC). A patient affected by MFC complaining central visual loss and scotoma in his left eye was fully investigated with dye-based angiographies, structural OCT and OCT-A. A reactivation of macular CNV was initially suspected, while OCT-A revealed the absence of any decorrelation signal both over the retinal pigment epithelium (RPE) and between RPE and Bruchs' membrane. OCT-A is a promising tool in detecting inflammatory CNV and in differentiating CNV from primitive inflammatory damage. Finely characterizing the aspect of a lesion allows us to choose the best therapeutic strategy for managing these potentially blinding diseases.

Published
2017

16. Hypotonic maculopathy secondary to scleral defect in atypical retinochoroidal coloboma

Author

Tito Fiore, Carlo Cagini, Fabrizio Giansanti, Adriana Pellegrino, Alessio Cerquaglia, and Marco Lupidi

Subjects
medicine.medical_specialty, Visual acuity, genetic structures, Tenon Capsule, Scleral Diseases, medicine.medical_treatment, Perforation (oil well), Visual Acuity, Retinochoroidal coloboma, Ocular Hypotension, Scleral buckle, Retina, 03 medical and health sciences, 0302 clinical medicine, Retinal Diseases, Ophthalmology, medicine, Humans, Scleral defect, Child, Papilledema, Coloboma, Rupture, Spontaneous, Choroid, business.industry, General Medicine, medicine.disease, Magnetic Resonance Imaging, eye diseases, Scleral Buckling, medicine.anatomical_structure, Medicine (all), 030221 ophthalmology & optometry, Maculopathy, Female, sense organs, medicine.symptom, business, Tomography, Optical Coherence, 030217 neurology & neurosurgery
Abstract

Purpose To describe a patient with unilateral hypotonic maculopathy and optic disc edema after spontaneous bulbar perforation of a full-thickness scleral defect. Methods An 11-year-old girl underwent scleral buckling surgery. Preoperative and postoperative evaluation included optical coherence tomography and high-resolution 3T magnetic resonance imaging. Results The scleral defect was covered with Tenon capsule sheaths and a meridional silicone buckle. One year postoperatively, visual acuity and macular and optic disc morphology were completely restored. Conclusions Ocular hypotony related to a defect of the sclera forming the roof of a retinochoroidal coloboma is a rare event. Hypotony was a consequence of a defect at the level of an atypical retinochoroidal coloboma where the scleral wall was found to be absent.

Published
2016

17. New Insights On Ocular Sarcoidosis: An Optical Coherence Tomography Angiography Study.

Author

Cerquaglia, Alessio, Iaccheri, Barbara, Fiore, Tito, Fruttini, Daniela, Belli, Federica Benedetta, Khairallah, Moncef, Lupidi, Marco, and Cagini, Carlo

Subjects
OPTICAL coherence tomography, SARCOIDOSIS, ANGIOGRAPHY, FLUORESCENCE angiography, SARCOIDOSIS diagnosis, RETINA, RESEARCH evaluation, CROSS-sectional method, RETROSPECTIVE studies, UVEITIS, VISUAL acuity, LONGITUDINAL method
Abstract

Purpose: To report optical coherence tomography angiography (OCT-A) findings in eyes with ocular sarcoidosis (OS) and to compare these findings with those of fluorescein angiography (FA). Methods: Observational, cross-sectional, case-control study. Patients presenting with OS involving the posterior segment were evaluated using FA, structural-OCT and OCT-A. OCT-angiograms of the superficial (SCP) and deep (DCP) capillary plexuses and choriocapillaris (CC) were qualitatively and quantitatively analyzed. Results: OCT-A seemed more sensitive than FA in detecting perifoveal capillary arcade disruptions, areas of hypoperfusion/non-perfusion and capillary abnormalities (p<0.05). Capillary hypoperfusion was more frequently detected in the DCP than in SCP, conversely capillary abnormalities were more often observed at the level of the SCP. Capillary vessel density values were significantly lower in eyes with OS than in healthy controls both at the level of DCP and CC (p<0.05). Conclusion: The depth-resolved nature of OCT-A allowed new insights on OS-induced microvascular and perfusion impairments. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. Tear Film Stability in Sjögren Syndrome Patients Treated with Hyaluronic Acid Versus Crosslinked Hyaluronic Acid-Based Eye Drops.

Author

Cagini, Carlo, Torroni, Giovanni, Fiore, Tito, Cerquaglia, Alessio, Lupidi, Marco, Aragona, Pasquale, and Iaccheri, Barbara

Subjects
SJOGREN'S syndrome, THERAPEUTIC use of hyaluronic acid, CROSSLINKED polymers, EYE drops, DRY eye syndromes, THERAPEUTICS, CHEMICAL reagents, COMPARATIVE studies, CORNEAL topography, HYALURONIC acid, RESEARCH methodology, MEDICAL cooperation, OPHTHALMIC drugs, RESEARCH, TEARS (Body fluid), VISUAL acuity, EVALUATION research, INTRAOCULAR drug administration
Abstract

Purpose: To compare the stability of the tear film after instillation of eye drops containing hyaluronic acid (HA) or crosslinked hyaluronic acid (CLHA)-based in patients with Sjögren syndrome-related dry eye (SSDE).Methods: Forty subjects were included in this study and were divided into 2 groups: the first group (control group) consisted of 20 healthy volunteers; the second group (study group) constituted of 20 suffering from SSDE; before and 5, 30, and 60 min after instillation of eye drops the surface regularity index (SRI) and surface asymmetry index (SAI) were registered.Results: Comparing HA and CLHA, in the control group, SAI show statistically significant difference in the time 0 and in time 5, whereas there is no a statistically significant difference after 30 and 60 min from instillation. For SRI there is no statistically significant difference at any time. In SSDE group there is no statistically significant difference in the time 0 and 5, whereas there is a statistically significant difference after 60 min for SAI, and after 30 and 60 min for SRI from instillation. Both SRI and SAI in dry eyes were significantly greater than in control eyes (P < 0.05).Conclusion: Our study showed a better efficacy of CLHA compared with HA in maintaining the stability of the tear film in a patient suffering from SSDE. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results